UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-34949 ARBUTUS BIOPHARMA CORPORATION (Exact Name of Registrant as Specified in Its Charter) British Columbia, Canada 98-0597776 (State ...

Arbutus Biopharma Corporation (NASDAQ:ABUS) Q3 2020 Earnings Conference Call November 5, 2020 8:45 AM ET Company Participants Pam Murphy - Investor Relations Bill Collier - President & Chief Executive Officer Dave Hastings - Chief Financial Officer Gaston Picchio - Chief Development Officer Mike Sofia - Chief Scientific Officer Conference Call Participants Mayank Mamtani - B. Riley Roy Buchanan - JMP Securities Operator Ladies and gentlemen, thank you for standing by and welcome to Arbutus Biopharma Corpora ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-34949 ARBUTUS BIOPHARMA CORPORATION (Exact Name of Registrant as Specified in Its Charter) British Columbia, Canada (State or Other Jurisdi ...

Arbutus Biopharma Corporation (NASDAQ:ABUS) Q2 2020 Earnings Conference Call August 7, 2020 8:45 AM ET Company Representatives Bill Collier - President, Chief Executive Officer Mike Sofia - Chief Scientific Officer Gaston Picchio - Chief Development Officer Dave Hastings - Chief Financial Officer Pam Murphy - Investor Relations Conference Call Participants Mayank Mamtani - B. Riley Roy Buchanan - JMP Securities Operator Ladies and gentlemen, thank you for standing by and welcome to the Arbutus Biopharma Cor ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-34949 | --- | --- | --- | --- | |---------------------------------------------------|------------------------------------------------- ...

Arbutus Biopharma Corporation (NASDAQ:ABUS) Q1 2020 Earnings Conference Call May 11, 2020 8:00 AM ET Company Participants Pam Murphy - Investor Relations Bill Collier - President & Chief Executive Officer Mike Sofia - Chief Scientific Officer Dave Hastings - Chief Financial Officer Gaston Picchio - Chief Development Officer Conference Call Participants Mayank Mamtani - B. Riley Operator Ladies and gentlemen, thank you for standing by, and welcome to the Arbutus Biopharma Corporation First Quarter 2020 Finan ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2019 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-34949 Arbutus Biopharma Corporation (Exact Name of Registrant as Specified in Its Charter) British Columbia, Canada 98-0597776 (State or Other ...